Advancing Regulatory Framework with AI: A Step Towards Quicker Medication

Abstract: While extending treatment protocols and refining systematic processes within the healthcare industry presents immense promise, artificial intelligence (AI) comes along with multiple benefits. It would arrive at accurate diagnoses of diseases, help generate personal-ized treatment plans, facilitate corporate interactions in healthcare systems, and benefit both patients and healthcare organizations. With the evolving trends in AI, the healthcare domain expects to see substantial effects in the coming few years, hence calling for strong regulation to ensure the protection of human ethics and practical application. The estab-lishment of common regulatory frameworks will enable responsible usages of AI while ac-centuating patient rights and privacy concerns. AI is changing how drug approvals are done through positive interventions on both the time and cost aspects. Whereas traditional drug development takes anywhere from 5.5 years to 14.5 years, AI has shortened this time frame for target discovery to a preclinical candidate to as little as 18 months. Furthermore, AI has reduced development costs by nearly 50%, thus rendering de-velopment more efficient while enhancing the accuracy of predictions of the efficacy and safety of drugs. The stepped integration of AI into drug approval processes accelerates in-novations by providing cost-effective solutions and enhancing precision that eventually benefits both patients and healthcare organizations.